26697-35-8

Usage

Chemical Properties

Red Solid

InChI:InChI=1/C13H12N2O3/c14-12-7-6-11(8-13(12)15(16)17)18-9-10-4-2-1-3-5-10/h1-8H,9,14H2

Upstream product

• 610-81-1 4-hydroxy-2-nitroaniline 
• 100-44-7 benzyl chloride 
• 100-51-6 benzyl alcohol 
• 103-90-2 4-acetaminophenol 
• 41927-14-4 N-[4-(benzyloxy)phenyl]acetamide 
• 100-39-0 benzyl bromide 
• 26697-34-7 N-(4-(benzyloxy)-2-nitrophenyl)acetamide 

Downstream Products

• 41927-17-7 4-(benzyloxy)-1,2-phenylenediamine 
• 238405-67-9 4-benzyloxy-2-nitrobenzenesulfonyl chloride 
• 755026-51-8 methyl 2-{[4-(benzyloxy)-2-nitrophenyl]amino}-4-chlorobenzoate 
• 755026-52-9 methyl 2-(2-amino-4-(benzyloxy)phenylamino)-4-chlorobenzoate 
• 894763-36-1 {[2-(bis-ethoxycarbonylmethyl-amino)-5-formyl-4-hydroxy-phenyl]-ethoxycarbonylmethyl-amino}-acetic acid ethyl ester 
• 894763-34-9 {[5-benzyloxy-2-(bis-ethoxycarbonylmethyl-amino)-phenyl]-ethoxycarbonylmethyl-amino}-acetic acid ethyl ester 
• 894763-35-0 {[5-benzyloxy-2-(bis-ethoxycarbonylmethyl-amino)-4-formyl-phenyl]-ethoxycarbonylmethyl-amino}-acetic acid ethyl ester 
• 894763-37-2 2-{(2-{bis-[(2-hydroxy-ethylcarbamoyl)-methyl]-amino}-4-formyl-5-hydroxy-phenyl)-[(2-hydroxy-ethylcarbamoyl)-methyl]-amino}-N-(2-hydroxy-ethyl)-acetamide 
• 238406-39-8 methyl 2(R)-2-(1,1-dioxido-7-phenyl-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl)propanoate 
• 529496-51-3 2-(1,1-dioxo-7-phenoxy-1,3,4,5-tetrahydro-1λ⁶-benzo[f][1,2,5]thiadiazepin-2-yl)-propionic acid methyl ester 
• 238405-68-0 N-(4-benzyloxy-2-nitrobenzenesulfonyl)-D-alanine methyl ester 
• 238405-71-5 methyl 2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanoate 
• 529496-50-2 2-[7-(4-methoxy-phenoxy)-1,1-dioxo-1,3,4,5-tetrahydro-1λ⁶-benzo[f][1,2,5]thiadiazepin-2-yl]-propionic acid methyl ester 
• 1026153-59-2 2-(4-benzyloxy-2-nitro-benzenesulfonylamino)-3-methyl-butyric acid tert-butyl ester 

Relevant academic research and scientific papers

INHIBITORS OF ENL/AF9 YEATS

Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula inhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.

Syntheses and pharmacokinetic evaluations of four metabolites of 2-(4-(2-((1H-benzo[d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)-N-(6-methyl-2,4-bis-(methylthio)pyridin-3-yl)acetamide hydrochloride [K-604], an acyl-CoA:cholesterol O-acyltransferase-1 inhibi

We synthesized and identified four metabolites of acyl-coenzyme A:cholesterol O-acyltransferase (ACAT)-1 inhibitor, K-604 (1). Two of the metabolites M1 and M2, were prepared from 1 using a combination reagent of hydrogen peroxide and sodium tungstate wit

Disperse scarlet dye compound, preparation method therefor and application of disperse scarlet dye compound

The invention discloses a disperse scarlet dye compound, a preparation method therefor and an application of the disperse scarlet dye compound. The disperse scarlet dye compound has a structure represented by a formula (I) shown in the description, wherein R is alkyl, alkoxy, halogen, nitro, cyano, a formula shown in the description or -OCH2CH=CH2. The invention provides the application of the disperse scarlet dye compound in printing and dyeing of hydrophobic textile materials. The disperse scarlet dye compound is bright-colored and beautiful in color and luster and has excellent washing fastness and sublimation fastness.

Benzofuroxane derivatives as multi-effective agents for the treatment of cardiovascular diabetic complications. Synthesis, functional evaluation, and molecular modeling studies

Diabetes mellitus is the major risk factor for cardiovascular disorders. Aldose reductase, the rate-limiting enzyme of the polyol pathway, plays a key role in the pathogenesis of diabetic complications. Accordingly, inhibition of this enzyme is emerging as a major therapeutic strategy for the treatment of hyperglycemia-induced cardiovascular pathologies. In this study, we describe a series of 5(6)-substituted benzofuroxane derivatives, 5a-k,m, synthesized as aldose reductase inhibitors. Besides inhibiting efficiently the target enzyme, 5a-k,m showed additional NO donor and antioxidant properties, thus emerging as novel multi-effective compounds. The benzyloxy derivative 5a, the most promising of the whole series, showed a well-balanced, multifunctional profile consisting of submicromolar ALR2 inhibitory efficacy (IC50 = 0.99 ± 0.02 μM), significant and spontaneous NO generation properties, and excellent hydroxyl radical scavenging activity. Computational studies of the novel compounds clarified the aldose reductase inhibitory profile observed, thus rationalizing structure-activity relationships of the whole series.

Functionalized alkoxy arene diazonium salts from paracetamol

Arene diazonium tetrafluoroborates can be synthesized from aromatic acetamides via a sequence of deacetylation, diazotation and precipitation, induced by anion exchange. The reaction is conducted as a convenient one-flask transformation with consecutive addition of the appropriate reagents. Exchange of solvents or removal of byproducts prior to isolation of the product is not required. The arene diazonium salts are isolated from the reaction mixture by simple filtration. Two complementary protocols are presented, and the utility of the reaction is exemplified for a synthesis of the diarylheptanoid natural product de-O-methyl centrolobine.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND

A compound represented bv the formula [I]: [wherein R1 and R2 are the same or different and each represents C1-6 alkyl, C3-8 cycloalkyl, et al; R3a, R3b, and R4 are the same or different and each represents hydrogen, C1-6 alkyl, et al; X represents -N-, -CH-, et al; Y1 represents a single bond, C1-3 alkylene, et al; Y2 represents C1-4 alkylene, oxy(C1-4 alkylene), et al; Ar1 represents a monocyclic aromatic carbocyclic group, monocyclic aromatic heterocyclic group, et al; and Ar2 represents a 5- or 6-membered aromatic carbocyclic group, aromatic heterocyclic group, et al]. This compound functions as a melanin-concentrating hormone receptor antagonist and is useful as, e.g., a therapeutic agent for obesity, et al.

METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE OR SALT THEREOF

The present invention is directed to a method for producing a cyclic diamine compound (3) or a salt thereof through the following scheme: (wherein Ar represents a phenyl group, a pyridyl group, or a pyrimidinyl group, any of which may have a substituent; X represents NH, S, or O; ring A represents a benzene ring or a pyridine ring, which may have a substituent; 1 represents an integer of 1 or 2; m represents an integer of 1 or 2; and n represents an integer of 1 to 6). The method enables synthesis of a cyclic diamine compound (3) or a salt thereof, which serves as an ACAT inhibitor, in an industrially useful manner.

Detecting Hg2+ ions with an ICT fluorescent sensor molecule: Remarkable emission spectra shift and unique selectivity

A fluorescent ratiometric Hg2+ ion sensor RMS, based on a coumarin platform coupled with a tetraamide receptor, is presented. This sensor, employing the ICT mechanism, could be used to specifically detect Hg 2+ ions in a neutral buff

Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-α converting enzyme inhibitors

Elevated levels of tumor necrosis factor-α (TNF-α) have been associated with several inflammatory diseases, and therefore, strategies for its suppression have become important targets in drug discovery. Our efforts to suppress TNF-α have centered on the i